ES2145803T3 - Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades. - Google Patents

Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades.

Info

Publication number
ES2145803T3
ES2145803T3 ES94118466T ES94118466T ES2145803T3 ES 2145803 T3 ES2145803 T3 ES 2145803T3 ES 94118466 T ES94118466 T ES 94118466T ES 94118466 T ES94118466 T ES 94118466T ES 2145803 T3 ES2145803 T3 ES 2145803T3
Authority
ES
Spain
Prior art keywords
cetrorelix
products
preparation
application
high dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94118466T
Other languages
English (en)
Inventor
Jurgen Prof Engel
Peter Dr Hilgard
Thomas Dr Reissmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Application granted granted Critical
Publication of ES2145803T3 publication Critical patent/ES2145803T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Tea And Coffee (AREA)

Abstract

PARA LA UTILIZACION EN LA TERAPIA DE ENFERMEDADES DE TUMORES BENIGNOS Y MALIGNOS SE DISPONE DEL PRODUCTO DE ACUERDO CON LA INVENCION, CONTENIENDO LA DOSIS INICIAL DE ACETATO DE CETRORELIX Y UNA O MULTIPLES DOSIS DE CUMPLIMENTACION DEL ACETATO DE CETRORELIX, EMBONATO DE CETRORELIX O UNA FORMA RETARDADA DE CETRORELIX, COMO PREPARADOS DE COMBINACION PARA UTILIZACION TEMPORAL DE TERAPIAS ESCALONADAS.
ES94118466T 1993-12-09 1994-11-24 Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades. Expired - Lifetime ES2145803T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4342091A DE4342091A1 (de) 1993-12-09 1993-12-09 Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten

Publications (1)

Publication Number Publication Date
ES2145803T3 true ES2145803T3 (es) 2000-07-16

Family

ID=6504624

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94118466T Expired - Lifetime ES2145803T3 (es) 1993-12-09 1994-11-24 Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades.

Country Status (10)

Country Link
US (1) US5663145A (es)
EP (1) EP0657170B1 (es)
JP (1) JP3439855B2 (es)
AT (1) ATE190495T1 (es)
CA (1) CA2137595C (es)
DE (2) DE4342091A1 (es)
DK (1) DK0657170T3 (es)
ES (1) ES2145803T3 (es)
GR (1) GR3033319T3 (es)
PT (1) PT657170E (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP0788799A3 (en) 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
DE19644994A1 (de) * 1996-10-30 1998-05-07 Asta Medica Ag Diagnostisches Mittel
US7005418B1 (en) * 1999-09-23 2006-02-28 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
BRPI0314546B8 (pt) * 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
KR20140091652A (ko) * 2010-12-06 2014-07-22 아스트론 리서치 리미티드 안정적이며 바로 사용 가능한 세트로레릭스 주사액

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT81285B (de) 1914-07-30 1920-09-10 I Gio Ansaldo & C S A I Gio Ah Verfahren zur thermischen Vorbehandlung von Stahl.Verfahren zur thermischen Vorbehandlung von Stahl.
GB1204580A (en) * 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3733407A (en) 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
DE2335265A1 (de) * 1973-07-09 1975-01-30 Schering Ag Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
US3969502A (en) 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
DE2729068A1 (de) * 1977-06-28 1979-01-11 Rainer Dr Med Liedtke Verfahren zur freisetzungssteuerung von arzneimitteln aus kapseln
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
EP0002495B1 (de) * 1977-12-14 1984-02-15 Asta-Werke Aktiengesellschaft Chemische Fabrik Erzeugnisse zur Anwendung in der cytostatischen Therapie
JPS5548064A (en) * 1978-03-03 1980-04-05 Yamanouchi Pharma Co Ltd Pressureereducing sealing vessel into which agent in protein is sealed
DE2834226A1 (de) * 1978-08-04 1980-02-28 Merck Patent Gmbh Presskoerper und verfahren sowie vorrichtung zu ihrer herstellung
JPS57166164A (en) * 1981-04-03 1982-10-13 Fujisawa Pharmaceutical Co Case for enclosing ampoule
US4415085A (en) * 1981-12-21 1983-11-15 Eli Lilly And Company Dry pharmaceutical system
DK90883A (da) * 1982-03-18 1983-09-19 Merck & Co Inc Beholder til osmotisk afgivelse af et stof eller en stofblanding
US4564363A (en) * 1983-07-13 1986-01-14 Smithkline Beckman Corporation Delayed action assembly
US4569927A (en) * 1984-02-23 1986-02-11 The Salk Institute For Biological Studies GnRH Antagonists IV
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
GB8518828D0 (en) * 1985-07-25 1985-08-29 American Home Prod Tablet package
US4817819A (en) * 1985-12-19 1989-04-04 Berlex Laboratories, Inc. Container for tablets
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
EP0268066A3 (en) * 1986-10-17 1990-07-11 Syntex (U.S.A.) Inc. Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
JPS63162619A (ja) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
WO1988004922A1 (fr) * 1986-12-25 1988-07-14 Teysan Pharmaceuticals Co., Ltd. Granule a dissolution lente et granule composite a effet persistant prepare a partir du premier granule
US5116818A (en) * 1987-03-10 1992-05-26 Medical College Of Hampton Roads Method and kit for contraception with GnRH-antagonist
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
GB2206046B (en) * 1987-06-25 1991-04-03 Alza Corp Multi-unit delivery system
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
JPH07552B2 (ja) * 1987-11-06 1995-01-11 田辺製薬株式会社 持効性製剤
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
SU1554911A1 (ru) * 1988-05-17 1990-04-07 Ленинградское Научно-Производственное Объединение Технологического Оборудования Для Производства Готовых Лекарственных Средств "Прогресс" Пенал дл гранулированных лекарств
US5036047A (en) * 1988-09-29 1991-07-30 Pitman-Moore, Inc. Method and composition for preventing conception
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
DK0463061T3 (da) * 1989-03-17 1993-07-12 Pitman Moore Inc Controlled-release tilførselsindretning til afgivelse af makromolekylære proteiner
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.

Also Published As

Publication number Publication date
PT657170E (pt) 2000-07-31
DE4342091A1 (de) 1995-06-14
JPH07194670A (ja) 1995-08-01
EP0657170A1 (de) 1995-06-14
EP0657170B1 (de) 2000-03-15
GR3033319T3 (en) 2000-09-29
DK0657170T3 (da) 2000-07-31
CA2137595A1 (en) 1995-06-10
US5663145A (en) 1997-09-02
JP3439855B2 (ja) 2003-08-25
ATE190495T1 (de) 2000-04-15
DE59409205D1 (de) 2000-04-20
CA2137595C (en) 2005-05-31

Similar Documents

Publication Publication Date Title
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
ES2145803T3 (es) Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades.
MX9304432A (es) Compuestos y formulaciones farmaceuticas para el tratamiento o prevencion de la osteoporosis y la perdida de los huesos.
EP0552256A4 (es)
ES2191034T3 (es) Formulaciones de liberacion controlada para la liberacion de metoprolol durante 24 horas.
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
ES2061799T3 (es) Nuevo preparado medicamentoso y procedimiento para su preparacion.
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ES2080307T3 (es) Composiciones farmaceuticas.
NO890186L (no) Fremgangsmaate for fremstilling av en avgivelses- og/ellerdoseringsform for legemiddelaktive stoffer.
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
ZA877901B (en) Active compounds for use in the treatment of tumors
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
AR002968A1 (es) Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica.
ES2107400T1 (es) Nueva utilizacion terapeutica de superoxidos dismutasas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 657170

Country of ref document: ES